Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis – the TryCort study by Uta Kiltz et al.
RESEARCH ARTICLE Open Access
Diagnostic value of a 3-day course of
prednisolone in patients with possible
rheumatoid arthritis – the TryCort study
Uta Kiltz1† , Christine von Zabern1†, Xenofon Baraliakos1, Frank Heldmann2, Bernd Mintrop1, Michael Sarholz1,
Dietmar Krause3, Friedrich Dybowski4, Ludwig Kalthoff5 and Jürgen Braun1*
Abstract
Background: In patients with tender and swollen finger joints, the differential diagnosis between rheumatoid
arthritis (RA) and osteoarthritis (OA) of the hands can be initially difficult. This prospective study (the TryCort study)
was performed to study the diagnostic value of prednisolone in differentiating between RA and hand OA. We
present the results of this potentially diagnostic test in patients with possible RA in daily clinical practice by
demonstrating the results of a pilot and a validation part of this ‘prednisolone test’ (pred-test).
Methods: We investigated the response to a 3-day course of 20 mg of prednisolone in patients with suspicion of
RA. All patients received 1 g of paracetamol per day for 5 days for pain relief. On days 3–5, a morning dose of
20 mg of prednisolone was added. Hand pain was quantified on a 0–10 Numerical Rating Scale, and the subjective
percentage of improvement (0–100%) was recorded. Thresholds for response to prednisolone were investigated in
a pilot phase with differentiation in response between patients with RA and patients with OA of the hands, both
with pain in the hands ≥4. In a validation phase, the best differentiating cut-off of the pilot phase was applied to
discriminate responders from non-responders in consecutive patients with hand pain ≥4 referred because of
suspected RA. Final diagnoses were made by the expert upon re-examination at week 12. Primary outcomes were
the sensitivity and specificity of a positive test in relation to the diagnosis.
Results: A percentage of 40% subjective improvement of pain in the hands on day 3 discriminated best between
RA and OA in the pilot phase. Among 95 patients with complete data in the validation phase, RA was diagnosed
in about 50%. Patients with RA had more swollen joints, higher C-reactive protein levels and slightly higher Health
Assessment Questionnaire scores. The pred-test was positive in 42.1% of all patients (40 of 95). The median
percentage of improvement on day 5 was higher in RA than in non-RA: 50% (IQR 30–60%) vs. 20% (IQR 10–30%)
(p < 0.001). The sensitivity and specificity of the pred-test were 0.6 (95% CI 0.5–0.8) and 0.8 (95% CI 0.7–0.9),
respectively, and the positive and negative predictive values were 0.77 and 0.70, respectively.
Conclusions: To our knowledge, this is the first evaluation of the widely used pred-test that has ever been
performed. The pred-test had a moderate sensitivity and a good specificity. We conclude that rheumatologists may
use this test in unclear clinical situations to better differentiate between inflammatory and other conditions.
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EudraCT number: 2011-002633-19. Registered on 21 Dec 2011.
* Correspondence: juergen.braun@elisabethgruppe.de
†Equal contributors
1Rheumazentrum Ruhrgebiet, Claudiusstraße 45, 44649 Herne, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kiltz et al. Arthritis Research & Therapy  (2017) 19:73 
DOI 10.1186/s13075-017-1279-z
Background
Joint pain of the hands is among the most frequent
symptoms and reasons for admission in rheumatology.
The biggest problem is arthralgia of the hands caused by
rheumatoid arthritis (RA) and/or hand osteoarthritis
(OA) [1]. In patients with tender and swollen finger
joints, the differential diagnosis between RA and OA can
be difficult, especially in relatively early disease stages
and also when the diseases overlap, and there is no
evidence that RA protects against OA or vice versa.
Current classification criteria are of limited help because
of their poor diagnostic utility in early and more ad-
vanced disease stages [2, 3]. Similarly, the specificity of
the RA classification criteria was 0.61, suggesting that
39% of the patients have a diagnosis other than RA [4].
In addition, many patients are initially diagnosed with
undifferentiated arthritis, and some of these patients will
fulfil RA classification criteria at later time points [5].
For the differential diagnosis between RA and OA, the
main question is usually whether the cause of arthralgia is
related to inflammation or to degenerative mechanisms.
However, even this differentiation is not so straightforward
anymore, because magnetic resonance imaging (MRI) find-
ings of synovitis and osteitis have also been described in
patients with OA [6]. Furthermore, involvement of the
distal interphalangeal joints may indicate OA rather than
RA. However, even this important clinical feature may be
misleading because the patient may well have both diseases
[7]. Clinically, there are different ways to potentially answer
the question of RA vs. OA – a clinically relevant question
because of the largely different therapeutic options [6, 8].
Of potential help for the differential diagnosis are patient
history and the presence of morning stiffness for >30 mi-
nutes, the joint pattern in the physical examination and/or
the patient history, and the obvious presence of swelling
and tenderness of joints. When taking technical procedures
into account, the measurement of biomarkers of inflamma-
tion, erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) may be useful to differentiate OA from RA.
For RA, there are even specific tests available, such as anti-
citrullinated peptide antibody (ACPA), which are also
believed to be of pathophysiological importance in terms of
their pathogenetic mechanism, which in part is also con-
nected to smoking habits of patients [8]. Finally, imaging
procedures may be helpful, especially those with the
capacity to visualize inflammation. MRI and ultrasound
techniques are now increasingly used to search for arthritis
and synovitis in both RA and OA [9, 10]. However, clinical
diagnosis is still considered the gold standard for a
diagnosis of these two most frequent rheumatic diseases.
However, there are patients and clinical situations where
even the totality of the evidence these tests and examina-
tions provide cannot definitively answer the clinical ques-
tion posed. At this point in time, many rheumatologists are
accustomed to just performing a short therapeutic attempt
with glucocorticoids (GCs). The effect of GCs in reducing
the inflammatory burden of arthritic conditions has been
well known for almost 70 years [11]. GCs still play an im-
portant role in international recommendations for the
treatment of RA [12, 13], and they are still frequently used
in daily practice [14]. The mechanisms of action are now
far better understood [15, 16]. The basic idea is that RA is
due to inflammation, whereas OA is either not based on
the same pathophysiology, or at least not to the same
degree. However, a short therapeutic attempt with GCs is a
clinical test whose diagnostic value has never been evalu-
ated. This prospective study (the TryCort study) was
performed to evaluate the diagnostic value of prednisolone
in differentiating between RA and hand OA.
Methods
Study design
The TryCort study was performed as a monocentric,
prospective clinical study to add another tool to improve
the diagnosis of RA. The study was planned in two
phases: a pilot and a validation study. The pilot part was
designed as a proof-of-concept study to investigate the
effect of a 3-day treatment intervention with 20 mg of
prednisolone (the ‘pred-test’) in patients with established
RA and hand OA. In detail, we wanted to determine the
‘cut-off ’ for response, and we also aimed to gain first insight
into the percentage of responders. The validation study was
designed to test the diagnostic utility of the pred-test and to
confirm the threshold of the treatment effect.
The ethics committee of the University of Muenster
approved the study protocol, and all patients gave
informed consent before participation. This study is
registered with EudraCT (2011-002633-19).
Study populations
Consecutive patients aged >18 years and <80 years pre-
senting to our hospital or two private practice offices of
cooperating rheumatologists were included in the study
between January 2012 and November 2014. In the pilot
phase, patients with pain in their fingers and/or hands and
either an established diagnosis of RA or an established
diagnosis of hand OA according to the treating rheuma-
tologist were eligible for enrolment into this first phase.
Patients with RA had to fulfil the American College of
Rheumatology (ACR)/European League Against Rheuma-
tism (EULAR) 2010 criteria for RA [2], and patients with
OA had to fulfil the ACR classification criteria for OA [3].
In the validation phase, patients with suspicion of RA
were eligible for enrolment into this phase. Suspicion of
RA was defined as chronic pain in fingers and hands last-
ing >6 weeks without other causality. The presence of pain
in finger joints was mandatory; pain in the hands (palm
and wrist) was not. Patients with hand OA fulfilling ACR
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classification criteria for OA but who were positive for
ACPA were not included in the trial. We excluded
patients with triggering factors for inflamed joints, such as
tophi, psoriasis or accidents.
For both groups, the degree of pain had to be ≥4 on a
0–10 Numerical Rating Scale (NRS). Patients receiving
concomitant treatment with oral GCs were not eligible.
In addition, patients who had been treated with oral
GCs of any dose within the 2 weeks before their baseline
visit were not included in the trial. In addition, patients
with uncontrolled diabetes mellitus, hypertension and
glaucoma, as well as those with pregnancy or desire to
become pregnant, were not eligible.
Interventions
All patients received 1 g of paracetamol/day for 5 days
(days 1–5) during the pilot and validation study to pro-
vide a background of pain reduction for ethical reasons
and comparability (Fig. 1). Rationale for paracetamol
was the low analgesic potency and the absence of an
anti-inflammatory effect so that medication could serve
as background medication without disturbing response
to GC therapy. Patients with an insufficient reduction of
pain could ask for an additional dose of paracetamol up to
a maximum of 2 g of paracetamol/day. Other analgesics or
non-steroidal anti-inflammatory drugs were not allowed
and were discontinued before the start of the study.
On days 3–5, a morning dose of 20 mg of prednisolone
was added. An intervention phase lasting about 3 days was
considered sufficient because prednisolone mediates a
quick anti-inflammatory response, but prednisolone re-
quires a 3-day interval to influence inflammation in joints.
Patients in the validation phase received the same trial
medication (paracetamol on days 1–5, prednisolone on
days 3–5) as patients in the pilot phase. Intervention on
days 1–5 in the validation phase was followed by an obser-
vational phase up to week 12. In this observational phase,
the patients did not receive study medication but might
receive therapy with disease-modifying anti-rheumatic
drugs (DMARDs) if RA had been diagnosed. The choice of
DMARD therapy was not pre-defined in the study protocol,
and the decision was up to the treating rheumatologist
(Fig. 1). Patients underwent re-examination by a rheuma-
tologist in week 12 to confirm the diagnosis made on day 5.
Re-examination consists of history, physical examination,
assessment of patient-reported outcomes and safety signals
and CRP measurement.
Outcome assessments
Pain in the hands was assessed on the basis of an NRS
score of 0–10 (0 = no pain, 10 = severe pain). The
improvement of pain was determined on a percentage
scale of 0–100% (0 = no improvement, 100% = optimal
improvement). The 68-joint count for swelling and ten-
derness was performed by one rheumatologist blinded to
laboratory and imaging data to exclude an influence of
these results on the physical examination.
Disease activity was measured using the 28-joint Disease
Activity Score (DAS28) [17] and the Rheumatoid Arthritis
Disease Activity Index (RADAI) [18]. Functional disability
was assessed by the Funktionsfragebogen Hannover (FFbH)
score, which strongly correlates with the Health Assess-
ment Questionnaire (HAQ) [19]. Values of FFbH were
converted into HAQ values by the published formula:
HAQ score = 3.16 − (0.028 × FFbH score). Grip strength
was evaluated by using a standard dynamometer. All
clinical measurements were recorded at each visit (days 1, 3
and 5 and week 12) in the afternoon. Time of day was
important to assess treatment response of the morning
prednisolone dose. Laboratory parameters measured
Fig. 1 Study design of the pilot (a) and validation (b) phases
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included CRP measured at days 1 and 5 and week 12, and
ACPA and rheumatoid factor measured at day 1.
Furthermore, all patients underwent the usual diag-
nostic procedures performed in our centre, independent
of the study design. The evaluation of conventional ra-
diographs and MRI was performed by an experienced
radiologist in our centre. Safety assessments were based
on reports of adverse events (AEs), routine physical ex-
aminations and vital signs, and laboratory test results
were documented in each visit. The clinical diagnosis of
an independent and experienced rheumatologist after
3 months was used as a gold standard.
Evaluation
The primary endpoint of the pilot phase was the propor-
tions of patients with RA and patients with OA with posi-
tive pred-tests. The pre-defined cut-off of 40% improvement
was applied to differentiate between responders and non-
responders. Thus, the pred-test was defined as being posi-
tive if patients had an improvement of ≥40% on day 5. The
primary endpoint of the validation phase was the sensitivity,
specificity and predictive value of the pred-test.
Statistical analysis
Descriptive data are presented as absolute values and
their proportions when referring to qualitative variables.
Continuous variables are expressed as the mean ± SD or
as the median with IQR (25–75% range) where appropri-
ate. The Mann-Whitney U test was used to compare the
data between subgroups at single time points. A p value
<0.05 was considered statistically significant. The diag-
nostic utility of the pred-test was determined by calcula-
ting the sensitivity, specificity and positive and negative
predicative values. AUC was analysed and graphically
plotted by using ROC curve analysis to show perfor-
mance of the cut-off values. For the statistical analysis,
IBM SPSS Statistics version 22 software (IBM, Armonk,
NY, USA) was used.
Results
A total of 132 patients were eligible for the study, 125 of
whom were included in the study: 30 in the pilot and 95
in the validation study (Fig. 2).
Pilot phase
A total of 15 patients with a confirmed diagnosis of RA
and 15 patients with a confirmed diagnosis of OA, re-
spectively, were included. In the RA group, there were 13
women (86.7%), and in the OA group, there were 11
women (73.3%). Demographic and clinical characteristics
of the patients are presented in Table 1.
Fig. 2 Flow diagram of the validation phase. RA Rheumatoid arthritis
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The mean age and symptom duration of the patients
with OA were somewhat higher than those of patients
with RA. The mean pain scores were similar in patients
with RA (5.4 ± 1.6) and patients with OA (5.3 ± 1.4).
However, patients with RA experienced a greater reduc-
tion in pain scores between days 1 and 5 to 2.9 ± 1.8
(RA) and 4.1 ± 1.5 (OA), respectively. The mean percent-
ages of improvement at day 5 (after 3 days of 20-mg
prednisolone therapy) were 52.3 ± 27.9% in the RA
group and 22.0 ± 20.1% in the OA group (Fig. 3).
The sensitivity and specificity for the cut-offs of sub-
jective improvement of 20%, 30%, 40% and 50% are
given in Table 2. The threshold of 40% of subjective im-
provement was selected as the best-performing cut-off,
so the pred-test was defined as being positive if the
patient reported a subjective improvement in hand
pain ≥40%. Applying this threshold, the pred-test was
positive in 11 patients with RA (73.3%) and 4 patients with
OA (26.7%) (Table 2) (p = 0.012). The sensitivity and
specificity for a diagnosis of RA were both 73.3%.
Validation phase
A total of 95 patients with pain in their fingers and
hands without a clear diagnosis were enrolled in the
validation phase and completed the 5 days of the
intervention. Of these 95 patients, 78 (82%) participated
in the final visit at week 12. According to the judgement
of the rheumatologist at week 12, 47 patients were diag-
nosed with RA and 48 with non-RA. The mean age and
symptom duration of the patients were rather similar in
patients with RA and subjects with non-RA (Table 1).
Patients with RA had more swollen joints, higher CRP
levels and comparable HAQ scores assessed on day 1
(Table 3).
Patients with RA experienced a more severe reduction
of pain during the treatment course with prednisolone.
Similarly, the median percentage of improvement at day
5 was higher in patients with RA than in those with
non-RA: 50% (IQR 30–60%) vs. 20% (IQR 10–30%)
(p = 0.001) (Fig. 3).
Overall, 40 (42.1%) of 95 patients had an improvement
of ≥40% on day 5, fulfilling the criteria of a positive
pred-test. More patients with RA than patients with
non-RA had a positive pred-test (31 patients with RA
[77.5%] vs. 9 patients with non-RA [22.5%]; p <0.001).
The sensitivity of the pred-test for a diagnosis of RA was
0.6 (95% CI 0.5–0.8), and the specificity was 0.8 (95% CI
0.7–0.9). The positive and negative predictive values
were 0.77 and 0.70, respectively. The ROC analysis
showed an AUC of 0.77 (95% CI 0.65–0.85) (Fig. 4).
The safety analysis showed that 23 patients (24.2%)
had AEs, and 16 AEs were considered drug-related
(5 headaches, 5 flushings, 2 tachycardia, 2 hypertension,
and 2 dizziness). There were no serious AEs.
Table 1 Demographic characteristics of the patients with rheumatoid arthritis, osteoarthritis in the pilot study and of patients with
rheumatoid arthritis and patients without rheumatoid arthritis in the validation study
Pilot phase Validation phase
RA (n = 15) OA (n = 15) RA (n = 47) Non-RA (n = 48)
Mean age, years 59.3 ± 6.3 66.8 ± 10.3 57.6 ± 12.2 54.5 ± 9.2
Female sex 86.7% 73.3% 70.2% 83.3%
Symptom duration, years 4.0 ± 3.5 10.8 ± 13.9 5.3 ± 10.2 4.9 ± 5.7
OA Osteoarthritis, RA Rheumatoid arthritis
Values are given as mean ± SD
Fig. 3 Difference between RA and non-RA regarding the mean
improvement of pain in the hands after prednisolone test in the
pilot and validation phases. RA Rheumatoid arthritis, OA Osteoarthritis
Table 2 Diagnostic utility of the different cut-offs
Cut-off of subjective
improvement
Pilot phase Validation phase
Sensitivitya Specificity Sensitivity Specificity
20% 93.3% 37.5% 79.2% 41.7%
30% 80.0% 66.7% 76.6% 58.3%
40% 73.3% 73.3% 66.0% 81.3%
50% 60.0% 80.0% 57.5% 91.7%
aBased on fourfold table
The safety analysis showed that ten patients (30%) had adverse events (AEs),
five of them with gastrointestinal complaints which were considered
drug-related AEs. No serious AEs were recognized
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Discussion
The TryCort study is the first evaluation of a widely used
test, the pred-test, that has ever been performed to
systematically investigate its diagnostic value in patients
with possible RA. The data document a statistically
significant association between positive responses to
GCs and a diagnosis of RA. Our hypothesis that more
patients with RA than patients with non-inflammatory
rheumatic conditions will improve when treated with
GCs was clearly confirmed and substantiated in both
study phases.
The anti-inflammatory properties of GCs are certainly
well established, and they are widely used to treat in-
flammatory rheumatic conditions such as RA [14, 20].
Accordingly, in a recent early arthritis cohort study, the
response to a GC bridging therapy at 2 weeks was
clearly predictive of having active disease at 3 months
[21]. In contrast to our study, the duration of the
intervention was much longer. Furthermore, the main
question of our study was different, because we studied
the diagnostic utility of GCs to diagnose inflammatory
arthritis and to differentiate RA from non-RA.
For many years, rheumatologists have been using a
short therapeutic attempt with prednisolone in unclear
clinical situations to differentiate between inflammatory
arthritis and non-inflammatory conditions. Our results
confirm that this test may indeed be useful in this re-
gard. The assumption that systemic GCs do not really
work in OA has recently been backed by the results of a
study in OA in which patients with OA reported no sig-
nificant pain reduction after treatment with 5 mg of
prednisolone for 4 weeks, although some synovitis had
been initially detected by MRI [6]. This is in contrast to
RA, where even low doses of prednisolone were shown
to be efficacious by reducing disease activity and to even
inhibit radiographic progression [14, 22, 23]. Therefore,
GCs have even been considered as DMARDs in RA [23],
and recent international recommendations have ad-
dressed all issues in connection with the use of prednis-
olone in RA [12, 24, 25]. Of interest, to provide help for
the clinical diagnosis, the diagnostic utility of prednisol-
one has also been studied in patients with chronic
obstructive pulmonary disease (COPD) [26], but no
meaningful diagnostic value was found. This may be
explained by the pathophysiologic differences between
COPD and RA.
Could the patients with early arthritis and arthralgia
involving hands and feet in our study have had rheuma-
tologic diagnoses other than RA? Several other inflam-
matory rheumatic diseases, such as psoriatic arthritis,
Table 3 Clinical characteristics of patients with rheumatoid arthritis and non-rheumatoid arthritis in the validation phase
Day 1 Day 5
Characteristic RA (n = 47) Non-RA (n = 48) p Value RA (n = 47) Non-RA (n = 48) p Value
Pain 6.1 ± 1.6 5.8 ± 1.6 0.3 3.4 ± 2.3 4.3 ± 1.8 <0.05
Swollen joint count 2.3 ± 2.4 1.4 ± 2.3 0.02 2.3 ± 4.3 1.1 ± 2.0 0.06
Tender joint count 13.0 ± 8.5 13.9 ± 10.5 0.7 12.0 ± 13.1 11.1 ± 8.9 0.8
CRP, mg/dl 0.5 ± 0.6 0.2 ± 0.3 0.03 0.4 ± 0.6 0.2 ± 0.1 0.1
DAS28 3.7 ± 0.8 3.3 ± 0.8 0.1 3.2 ± 1.0 3.1 ± 0.8 0.7
RADAI 5.0 ± 1.4 4.6 ± 1.2 0.2 3.7 ± 1.53 4.0 ± 1.33 0.4
HAQ 1.2 ± 0.6 1.1 ± 0.4 0.8 1.0 ± 0.5 1.1 ± 0.4 0.2
Grip strength, Pascal 40.2 ± 21.8 35.8 ± 17.6 0.4 38.4 ± 22.1 43.4 ± 26.2 0.5
Abbreviations: CRP C-reactive protein, DAS28 28-Joint Disease Activity Score, HAQ Health Assessment Questionnaire, RA Rheumatoid arthritis, RADAI Rheumatoid
Arthritis Disease Activity Index
Values are given as mean ± SD
Assessment: CRP <0.5 mg/dl, DAS28 range 0–10, grip strength range 0–1.0, HAQ range 0–3, pain NRS range 0–10, RADAI range 0–10, swollen joint count range
0–66, Tender joint count range 0–68
Fig. 4 ROC curve of the diagnostic utility of the prednisolone test in
the validation phase
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connective tissue diseases and even vasculitides, are
known to possibly present with a similar picture [27].
Establishing a differential diagnosis was therefore one of
the key elements before including patients in the study.
However, because the gold standard of our test was a
clinical diagnosis of an independent and experienced
rheumatologist after 3 months, we cannot be perfectly
sure that we included patients with other inflammatory
arthritic conditions of the hand. As stated in the
Methods section above, we tried to minimize this bias
by performing a standard diagnostic work-up for every
patient. Furthermore, many patients have to be classified
as having undifferentiated arthritis because they do not fit
into one of the well-defined categories. However, patients
may well progress from an initial classification of undiffer-
entiated arthritis to RA [5]. In any case, the response to
therapy was similar in a large recent study [28].
Because the early classification of RA may be difficult,
in this study we decided to rely on an expert’s diagnosis
after an observational period of 12 weeks. However, we
are aware that even this period of time may not be long
enough to finally ascertain a diagnosis of RA. Thus, we
cannot exclude that some patients with a diagnosis of
possible RA would have been diagnosed differently at
later time points. Other diagnoses would include, for ex-
ample, psoriatic arthritis and undifferentiated arthritis.
Because there is some evidence that MRI does not dif-
ferentiate patients with established RA from other forms
of early arthritis, we could not use such results for this
purpose [29]. We are aware that symptom duration of ap-
proximately 5 years in our patient population (validation
cohort) might be a matter of debate. However, in patients
with arthralgia but without clear synovitis, diagnosis is
often delayed and is even seen in registry cohorts [30].
The ACR/EULAR classification criteria for RA require
at least one swollen joint [2]. The data of our study
showed that one-third of the patients diagnosed with RA
initially had clinically no clear swollen joints (the main
inclusion criterion for this study was finger and hand
pain) but MRI changes suggestive of synovitis. Because it
is now well established that early diagnosis and treat-
ment are critical for patients with RA [8, 31], we think
that our study gives a first hint that the response to GCs
could become an important component of diagnosing
and treating patients with RA at early time points and
when the ACR/EULAR criteria are not reliably fulfilled.
Of course, the prognostic significance of this test needs
to be assessed in studies with a different design.
Our pilot study revealed that a 40% improvement was
the best choice between sensitivity and specificity re-
garding a diagnosis of RA. The ACR 20% improvement
criteria (ACR20) are widely used in RA trials [32, 33].
However, their performance related to discrimination is
known not to be optimal [34]. Indeed, the ACR50
criteria seem to be superior [35]. Our evaluation for this
diagnostic test showed a moderate sensitivity of 65.9%
with a good specificity of 81.2%. Thus, our pred-test per-
formed well, but it did not perform perfectly well. Pos-
sible reasons are our inhomogeneous patient cohort,
lack of an objective gold standard for diagnosis and arbi-
trarily chosen time point for diagnostic testing. Some of
these aspects (e.g., symptom duration) might have had
an impact on test accuracy, but this cannot be quantified
within our study design.
We are aware that the pred-test without confirmation
of other surrogate markers is not helpful in clinical
decision-making processes. We therefore recommend
use of the test in light of other confirming factors, such
as history, physical examination, imaging and laboratory
results. Whether the test is useful in the hands of pri-
mary care doctors cannot be answered by our study.
However, we think that the pred-test can triage patients
from primary care to rheumatology specialists.
On one hand, a positive test result will help to identify
patients with inflammatory arthritis, especially RA, who
are then subject to proper treatment. In case of a nega-
tive test result, the likelihood of RA is low. However, a
re-evaluation may still be necessary if suggestive symp-
toms appear. Nevertheless, may a negative test result
prevent patients from receiving unnecessary treatment
with GCs?
On the other hand, our study also shows that 4 of 15 pa-
tients in the pilot phase and 15 of 47 patients diagnosed
with RA in the validation phase had a negative test result.
One possible explanation for this is that some patients
may need higher doses of GCs. Indeed, the Combination
Therapy for Rheumatoid Arthritis (COBRA) study showed
that a high GC dose of 60 mg/day worked well in many
patients with RA [36]. Ever since then, also starting doses
of 10 mg/day have been used to reach remission [37, 38],
but for maintenance therapy, even dosages <5 mg/day
have been successful in some patients [39]. In an ongoing
study, the performance of two GC doses were compared
in patients with early RA [40]. Different tapering strategies
have been proposed [24]. Especially, the questions of
which patients may need higher dosages of prednisolone
and why deserve further study. GC receptors may have a
role in this [16]. Another possibility is that, in addition to
RA, there may be other reasons for pain, such as OA, and
the patient is unable to differentiate between the two.
Conclusions
This study shows that the pred-test can support clinical
decision-making as a diagnostic aid in differentiating
between RA and non-RA. These data also confirm a cut-
off point of ≥40% improvement with good sensitivity
and specificity. The study also clearly shows that a
positive response to prednisolone cannot be taken as
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evidence that a diagnosis of RA is a given. Further
studies are needed to confirm the diagnostic utility of
the pred-test with larger patient groups in rheumatology
as well as in primary care. Future research can be
focused on test accuracy in the light of possible
influencing factors.
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